|Year : 2017 | Volume
| Issue : 3 | Page : 159-163
Correlates of brain derived neurotrophic factor in children with attention deficit hyperactivity disorder: A case-control study
Hala Taha1, Eman Elsheshtawy2, Soheir Ibrahim Mohamed1, Omnia Al-Azazzy1, Mohamed Elsayed3, Salah Al Sayed Ibrahim4
1 Psychiatric Dep.AL-Azhar university, Egypt
2 Psychiatric Dep.Mansoura university, Egypt
3 Psychiatric Dep. Mansoura Faculty of Medicine, zagazig university, Egypt
4 Clinical pathology Dep.,zagazig university, Egypt
|Date of Submission||08-May-2017|
|Date of Acceptance||25-May-2017|
|Date of Web Publication||25-Oct-2017|
Ass. Prof. of Psychiatry, Psychiatry Department, Faculty of Medicine, AL-Azhar University
Source of Support: None, Conflict of Interest: None
Brain derived neurotrophic factor (BDNF) appears to intervene in the pathogenesis and treatment response in Attention deficit hyperactivity disorder (ADHD), based on the conceptualization of ADHD as a neurodevelopmental disorder and the importance of the BDNF for normal neural development.
To estimate the difference in the serum level of BDNF in children diagnosed with ADHD and normal control, find its clinical correlates and to search which factors could predict abnormal level of BDNF.
Subjects and methods
A case control study was done on 35 child newly diagnosed untreated ADHD, control group of 30 healthy children. All were subjected to IQ test (Stanford-Binet), Conner’s test to assess severity of different symptoms. Blood sample to determine the level of BDNF.
Serum level BDNF was significantly higher in children with ADHD (0.1596±0.0909 ngm). BDNF was positively correlated with cognitive problems (r=0.345) and negatively correlated with age and IQ (r=−0.399, −0.383 respectively). Predictors for high level of BDNF were age (beta=−0.368), IQ (beta=−0.368) and inattention (beta=0.422).
High serum level of BDNF in children with ADHD could have a role in the etiology of ADHD, affecting cognition and intelligence. The presence of inattention and low intelligence can predict high level of BDNF.
Keywords: ADHD, BDNF, Egypt, intelligence, predictors
|How to cite this article:|
Taha H, Elsheshtawy E, Mohamed SI, Al-Azazzy O, Elsayed M, Ibrahim SA. Correlates of brain derived neurotrophic factor in children with attention deficit hyperactivity disorder: A case-control study. Egypt J Psychiatr 2017;38:159-63
|How to cite this URL:|
Taha H, Elsheshtawy E, Mohamed SI, Al-Azazzy O, Elsayed M, Ibrahim SA. Correlates of brain derived neurotrophic factor in children with attention deficit hyperactivity disorder: A case-control study. Egypt J Psychiatr [serial online] 2017 [cited 2023 Dec 10];38:159-63. Available from: https://new.ejpsy.eg.net//text.asp?2017/38/3/159/217207
| Introduction|| |
ADHD is considered as a neurodevelopmental disorder which is characterized by severe and age-inappropriate levels of inattention and hyperactivity/impulsivity that are present in at least two areas of life for over 6 months (, 2013). Though after decades of research, the causes of ADHD are still unknown.
Data from neuroimaging, neurochemical and genetics studies in patients with ADHD have evidenced both functional and structural alterations in development in different brain areas (Cortese, 2012). Molecules implicated in neuroplasticity at these areas may potentially have a role in the pathogenetic mechanisms.
Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a key role in the regulation of neurogenesis and differentiation of neural pathways during neurodevelopment. Also, it has a role in the modulation of synaptic plasticity and dendritic growth in the adult brain (Vicario-Abejon et al., 2002; Chapleau and Pozzo-Miller, 2007).
BDNF is expressed during periods critical for cognitive development where the expression of BDNF differs by brain regions. Highest BDNF expression in the temporal cortex occurs in infancy, and decreases with age, whereas in young adulthood peak BDNF expression in frontal cortex occur. BDNF expression in the hippocampus remains relatively constant over the lifespan (Webster et al., 2006). Frontal brain regions develop more slowly than other regions, which have protracted developmental trajectories in the frontal cortex which parallel those of children’s cognitive and academic abilities (Kaja et al., 2016).
Mature BDNF is initially synthesized as a precursor protein Pro-BDNF which is converted to mature BDNF by extracellular proteases. Mature BDNF is biologically active. Both proBDNF and mature BDNF play important roles in several physiological functions of neurons, might be related to the pathology of psychiatric disorders as major depression (Jiang and Salton, 2013), schizophrenia (Martinotti et al., 2012), bipolar disorder (Fernandes et al., 2011) and obsessive–compulsive disorder (Maina et al., 2010). Similarly, also in childhood neurodevelopment disorders such as autism (Katoh-Semba et al., 2007) and ADHD.
BDNF appears to intervene in the pathogenesis and treatment response in Attention deficit hyperactivity disorder (ADHD), based on the conceptualization of ADHD as a neurodevelopmental disorder and the importance of the BDNF for normal neural development. In addition, in experimental models, psycho-stimulants and antidepressants increase the brain concentration of BDNF (Carballo et al., 2012).
BDNF is found in both human serum and plasma, where platelets contain large amount of BDNF (Fujimura et al., 2002). Serum levels of BDNF have been found to be 200-fold higher than plasma levels (Rosenfeld et al., 1995). Therefore, the difference between serum and plasma levels of BDNF could reflect the amount of BDNF stored in circulating platelets.
Because of the discrepancies in different studies between plasma and serum level of BDNF in children with ADHD, we aimed at estimating the difference in the serum level of BDNF in children diagnosed with ADHD and normal control, find its clinical correlates and to search which factors could predict abnormal level of BDNF.
| Subjects and methods|| |
This is a case-control study that was carried from May 2016 to September 2016. A convenient sample of 65 children 35 with ADHD and 30 control − groups were enrolled. ADHD children were recruited from outpatient clinic of el-zahraa Hospital. Inclusion criteria were: Children newly diagnosed with ADHD before starting treatment, both sexes, age from 5–13 years. Exclusion criteria were: neurological disorders, ASD, IQ below 70, other comorbidity.
All children were subjected to: a- complete physical examination.
b- Psychometric assessment for diagnosing ADHD using structured clinical interview for assessments of psychiatric disorders in childhood according to DSM IV Criteria (Hien et al., 2004).
Intelligence quotient (IQ) using Stanford Binet Intelligence test which is a standardized test that assesses IQ and cognitive abilities in children and adults aged 2 to 23. It tests four areas of intelligence; verbal reasoning, quantitative reasoning, abstract and visual reasoning and short-term memory skills (Terman and Merrill, 1960). Arabic version was used (Melika, 1998).
The symptomatology of ADHD were assessed using Conner’s Parent Rating Scale-revised, long version (Conners, 1989). The Arabic version was used in this study which was translated and validated through previous research conducted by Al-Behairy and Aglaan (2009).
Control-group participants were recruited from Pediatric Department of el-zahraa hospital who were matched in age, sex, residency, socioeconomic class and body mass index. They were selected free from any developmental disease or exhibiting serious behavioral problems as determined through parent and teacher history. Parents or Guardians provided written informed consent according to ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Children or adolescents provided verbal assent regarding participation in this study.
Blood sample collection
For ADHD patients and control group, 3 ml blood samples were collected from the participant’s antecubital veins in a plain tube. All samples were allowed to clot for 2 hours at room temperature then centrifuged for 15 minutes at 1000×g samples were clear. The supernatant was collected and stored at −20 0C until assays of serum Human BDNF which was assayed using ELISA Human BDNF. ELISA KIT were obtained from Elab science Catalog No:E-e-H0010.
This ELISA kit uses Sandwich-ELISA as the method. The micro ELISA plate provided in this kit was pre-coated with an antibody specific to Human BDNF. Standards or samples were added to the appropriate micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for BDNF and Avidin- Horseradish peroxidase (HRP) conjugate was added to each micro plate well successively and incubated. Free components were washed away. The substrate solution was added to each well. Only those wells that contain Human BDNF, biotinylated detection antibody and Avidin-HRP conjugate had appeared blue in color. The enzyme- substrate reaction was terminated by adding of a sulphuric acid solution and the color turns yellow. The optical density (OD) was measured spectrophotometrically at a wavelength of 450 nm+_2 nm.The OD value was proportional to the concentration of BDNF. For calculation of BDNF concentration, the OD of the sample was compared to the standard curve.
Data were entered into the SPSS for Windows (version 15.0; SPSS Inc., Chicago, IL, USA) and were analyzed using descriptive and analytic analyses including frequencies, mean and standard deviations, percent, t-test, and chi-square test for comparison of quantitative and qualitative variables, respectively, F test for comparison of 3 groups. Pearson correlation coefficients, stepwise regression analysis was done to detect predictors. A P value of ≤0.05 was considered significant in all analyses.
| Results|| |
[Table 1] demonstrate that both patients and control groups were matched regarding age, gender and mean IQ. More than half of the patient group were hyperactive, 20% were inattentive. The level of BDNF was higher in the patient group (mean=0.1596±0.0909 ngm) and was statistically significant different from control ([Table 2]).
|Table 1: Difference between patients & control regarding different clinical parameters, BDNF level|
Click here to view
|Table 2: Correlation between BDNF, different psychological, psychometric parameters|
Click here to view
BDNF was positively correlated with cognitive problems (r=0.345) and negatively correlated with age and IQ (r=−0.399, −0.383 respectively) ([Table 3]).
|Table 3: Comparison between different subtypes of ADHD using analysis of variance|
Click here to view
On comparing between different subtypes of ADHD, there weren’t any significant difference between them regarding IO and BDNF level (P=0.310, P=0.116 respectively). Highly significant statistical differences were observed in the subscales of Conner’s test as cognitive problems, hyperactivity, inattention and hyperactivity-impulsivity (P=0.001) ([Table 4]).
Predictors for high level of BDNF were age (beta=−0.368), IQ (beta=−0.368) and inattention (beta=0.422).
| Discussion|| |
In this study we aimed to investigate the difference in the level of BDNF between children with ADHD and normal control, also to define its relation to different clinical features. There was significant statistical difference between patients and control regarding the level of BDNF. The increased BDNF could reflect a compensatory mechanism in the response of abnormal and late brain maturation. This was supported by a previous studies) Shim et al., 2008; Reda et al., 2016; Yeom et al., 2016). Others don’t find any difference as in studies of Scassellati et al. (2014), Sayyah (2009). This difference could be related to different sampling method, or some possible confounding factors in BDNF measures, such as motor activity, exercise or diet.
In our study BDNF level was correlated negatively with age and it increases in younger age group and was found to be a predictor of raised BDNF level. This was supported by the study of Katoh-Semba et al. (2007) who have reported that there is increased serum BDNF level over the first several years and, then decreases after reaching adult levels in humans. Also, by a study made by Corominas-Roso et al. (2013) who reported that adults with ADHD (mean age: 33.43±8.99 years) have lower BDNF levels than control adults.
BDNF was found to be negatively correlated with total intelligence and low intelligence was found to be a predictor of high BDNF. This was supported by previous studies of Yeom et al. (2016), Sayyah (2009) and Taurines et al. (2014), who reported that BDNF was correlated with total IQ and verbal IQ but not with performance IQ. They suggested that dysregulated BDNF may play a role in the development of intellectual disability and found that it can be used as an early biomarker for identification of intellectual disability. Elevated BDNF levels may reflect an abnormal state in prenatal or early postnatal neuronal development.
High level of BDNF was correlated with cognitive problems as detected by a subtest of Conner’s scale which was supported by the study of Sayyah (2009) and Yeom et al. (2016). Altered cognition together with affected intelligence could reflect a relationship between a polymorphism of the BDNF gene and cognitive functions in humans which was found in studies of Egan et al. (2003), Hariri et al. (2003) and Lang et al. (2009). The latter reported that the Val66Met polymorphism of the BDNF gene, valine (Val) to methionine (Met) substitution at codon 66, is associated with poor episodic memory, abnormal hippocampal activation, abnormal intracellular trafficking and dys-regulation of BDNF secretion. This result coincides with a study with Yeom et al. (2016), who found similar results in normal preschool children as it is thought that excess BDNF may interfere with normal learning and memory. Also with a study of Vyas and Puri (2012) who reported that BDNF genotype may play a role in cognitive functions and different dimensions of intelligence.
No significant difference between various subtypes of ADHD regarding IQ and BDNF while there were significant differences regarding various sub items of Conner’s scale according to the diagnostic subtype.
From the predictors of raised level of BDNF is inattention. This was supported by previous studies of Tsai (2007) and Sayyah (2009), who found a correlation between severity of inattention and raised BDNF. As it was supposed that adequate, physiological amount of BDNF is essential for learning and memory while either increased or decreased level of BDNF will lead to loss of synaptic refinement with impaired learning and memory (Cunha et al., 2010).
| Conclusions & recommendation|| |
BDNF level is high in the serum of children with ADHD. BDNF correlated positively with cognitive problems, negatively with age and IQ. Predictors for elevated BDNF are lower age, low IQ and presence of inattention.
Future studies are needed for cognitive, neuropsychological and psychopathological assessment in a larger sample could be useful to clarify the involvement of BDNF in the phenotype characterization of ADHD. Further studies are required to determine the source of BDNF whether platelet, plasma, serum or whole blood. 
This study is cross-sectional done at one setting, thus, a more longitudinal studies are needed to determine which variables could have an effect on the level of BDNF. The influence of motor activity, diet and exercise on BDNF weren’t considered in this study. Also, small number of the sample, including higher number of subjects would increase statistical power. This would limit the generalizability of the results.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
APA (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, DSM-5. Arlington, VA: American Psychiatric Association.
Al-Behairy A, Aglaan A (2009). Conner’s’ Rating scales. Egypt: Dar El Nahda.
Carballo AM, Mill IC, Ramos R, Casas IM, Chova FC, Francisco Moreno FM et al.
(2012). Different basal concentration and different response of BDNF to prolonged release methylphenidate between ADHD subtypes. European Journal of Psychotraumatology 3:1–1.
Chapleau CA, Pozzo-Miller L (2007). Activity-dependent structural plasticity of dendritic spines. In: Byrne J, editor. Concise learning and memory: the editor’s selection. Oxford: Elsevier. 281–305.
Conners CK (1989). Conners rating scales manual, North Tonawanda, NY: Multi-Health Systems.
Corominas-Roso M, Ramos-Quiroga JA, Ribases M, Sanchez-Mora C, Palomar G, Valero S et al.
(2013). Decreased serum levels of brain-derived neurotrophic factor in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 16:1267–1275.
Cortese S (2012). The neurobiology and genetics of attention-deficit/hyperactivity disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol 16:422–433.
Cunha C, Brambilla R, Thomas KL (2010). A simple role for BDNF in learning and memory? Front Mol Neurosci 3:1.
Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al.
(2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257–269.
Fernandes BS, Gama CS, Maria Ceresér K, Yatham LN, Fries GR, Colpo G et al.
(2011). Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 5:1–10.
Fujimura H, Altar CA, Chen R et al.
(2002). Brain derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 87:728–734. 16
Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, Weinberger DR (2003). Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23:6690–6694.
Hien D, Matzner F, First M, Spitzer R, Williams J, Gibbon M (2004). Structured clinical interview for DSM IV childhood diagnoses. New York: Biometrics Research.
Jiang C, Salton SR (2013). The role of neurotrophins in major depressive disorder. Trens Neurosci 4:46–58.
Kaja K, Molfese PJ, Kornilov SA, Mencl WE, Frost SJ, Lee M et al.
(2016). The BDNF Val66Met Polymorphism Influences Reading Ability and Patterns of Neural Activation in Children. PLoS One 11:e0157449. http://dx.doi.org/10.1371/journal.pone.0157449
Katoh-Semba R, Wakako R, Komori T, Shigemi H, Miyazaki N, Ito H et al.
(2007). Age-related changes in BDNF protein levels in human serum: differences between autism cases and normal controls. Int J Dev Neurosci 25:367–372.
Lang UE, Hellweg R, Sander T, Gallinat J (2009). The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry 14:120–122.
Maina G, Rosso G, Zanardini R, Bogetto F, Gennarelli M, Bocchio-Chiavetto L (2010). Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients: a case-control study. J Affect Disord 122:174–178.
Martinotti G, Di Iorio G, Marini S, Ricci V, De Berardis D, Di Giannantonio M (2012). Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review. J Biol Regul Homeost Agents 26:347–356.
Melika LK (1998). Standard Binet IQ test. 4th ed. Cairo, Egypt: Dar El Nahda.
Reda Mona, El-Nady Hala G, Rabie Menan A, Fawzy Rania, Adel Shaymaa, AwadAllah Eman, Moneim Mohamed A (2016). Comparing brain-derived neurotrophic factor levels, intelligence, and memory in clinical subtypes of attention-deficit hyperactivity disorder. Middle East Current Psychiatry 23:56–62. doi: 10.1097/01.XME. 0000481814.92893.e2
Rosenfeld RD, Zeni L, Haniu M et al.
(1995). Purification and identification of brain-derived neurotrophic factor from human serum. Protein Expr Purif 6:465–471.
Sayyah H (2009). BDNF Plasma level in ADHD Children; Correlation to Different Symptomatology. Current Psychiatry 16:284–294.
Scassellati C, Zanardini R, Tiberti A, Pezzani M, Valenti V, Effedri P et al.
(2014). Serum brain-derived neurotrophic factor (BDNF) levels in attention deficit–hyperactivity disorder (ADHD). European Child & Adolescent Psychiatry 23:173–177.
Shim SH, Hwangbo Y, Kwon YJ, Jeong HY, Lee BH, Lee HJ et al.
(2008). Increased levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention deficit-hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry 32:1824–1828.
Taurines R, Segura M, Schecklmann M, Albantakis L, Grunblatt E, Walitza S et al.
(2014). Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder. J Neural Transm 121:1117–11128.
Terman LM, Merrill MA (1960). Standard Binet Intelligence Scale. Houghton, Boston: Quoted from: Roid, G. H. (2003). Standard Binet Intelligence Scale; 5th, Maker Role Publisher
Tsai SJ (2007). Attention-deficit hyperactivity disorder may be associated with decreased central brain derived neurotrophic factor activity: clinical and therapeutic implications. Med Hypotheses 68:896–899.
Vicario-Abejon C, Owens D, McKay R, Segal M (2002). Role of neurotrophins in central synapse formation and stabilization. Nat Rev Neurosci 3:965–974.
Vyas NS, Puri BK. (2012). Evidence for an association between brain-derived neurotrophic factor Val66Met gene polymorphism and general intellectual ability in early-onset schizophrenia. Isr J Psychiatry Relat Sci 49:137–142.
Webster MJ, Herman MM, Kleinman JE, Shannon Weickert C (2006). BDNF and trkB mRNA expression in the hippocampus and temporal cortex during the human lifespan. Gene Expression Patterns 6:941–951.
Yeom CW, Park YJ, Choi SW, Bhang SY (2016). Association of peripheral BDNF level with cognition, attention and behavior in preschool children. Child and Adolescent Psychiatry and Mental Health 10:10. 2016; DOI: 10.1186/s13034-016-0097-4
[Table 1], [Table 2], [Table 3], [Table 4]
|This article has been cited by|
||Brain-derived neurotrophic factor (BDNF) levels in children and adolescents before and after stimulant use a systematic review and metanalysis
| ||Marina Silva de Lucca, Maria Eduarda Oliveira Pimentel, Cleuberton Kenedy Oliveira Raimundo, Bruno David Henriques, Tiago Ricardo Moreira, Sílvia Almeida Cardoso, Débora Marques de Miranda |
| ||Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2023; : 110761 |
|[Pubmed] | [DOI]|
||Plasma brain-derived neurotrophic factor (BDNF) in Egyptian children with attention deficit hyperactivity disorder
| ||Reem El Ghamry,Mona El-Sheikh,Marwa Abdel Meguid,Safi Nagib,Dina Aly El Gabry |
| ||Middle East Current Psychiatry. 2021; 28(1) |
|[Pubmed] | [DOI]|
||Exploring the role of BDNF DNA methylation and hydroxymethylation in patients with obsessive compulsive disorder
| ||Claudio DæAddario,Fabio Bellia,Beatrice Benatti,Benedetta Grancini,Matteo Vismara,Mariangela Pucci,Vera De Carlo,Daniela Galimberti,Chiara Fenoglio,Elio Scarpini,Mauro Maccarrone,Bernardo Dell’Osso |
| ||Journal of Psychiatric Research. 2019; |
|[Pubmed] | [DOI]|